Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?
Breccia M, Frustaci AM, Cannella L, Soverini S, Stefanizzi C, Federico V, Grammatico S, Santopietro M, Alimena G. Breccia M, et al. Among authors: santopietro m. Cancer Chemother Pharmacol. 2009 Jun;64(1):195-7. doi: 10.1007/s00280-008-0905-5. Epub 2009 Jan 21. Cancer Chemother Pharmacol. 2009. PMID: 19156415
"Real-life" results of front-line treatment with Imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemia.
Latagliata R, Breccia M, Carmosino I, Cannella L, De Cuia R, Diverio D, Frustaci A, Loglisci G, Mancini M, Santopietro M, Stefanizzi C, Volpicelli P, Vozella F, Alimena G. Latagliata R, et al. Among authors: santopietro m. Leuk Res. 2010 Nov;34(11):1472-5. doi: 10.1016/j.leukres.2010.07.001. Epub 2010 Aug 13. Leuk Res. 2010. PMID: 20708799
Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase.
Breccia M, Girmenia C, Latagliata R, Loglisci G, Santopietro M, Federico V, Petrucci L, Serrao A, Salaroli A, Alimena G. Breccia M, et al. Among authors: santopietro m. Mediterr J Hematol Infect Dis. 2011;3(1):e2011021. doi: 10.4084/MJHID.2011.021. Epub 2011 May 16. Mediterr J Hematol Infect Dis. 2011. PMID: 21713076 Free PMC article.
Complete clearance of Ph+ metaphases after 3 months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemia.
Latagliata R, Isidori A, Breccia M, Carmosino I, Vozella F, Volpicelli P, Finsinger P, Barulli S, Loglisci G, Santopietro M, Federico V, Diverio D, Nanni M, Mancini M, Visani G, Alimena G. Latagliata R, et al. Among authors: santopietro m. Acta Haematol. 2013;129(2):126-34. doi: 10.1159/000343384. Epub 2012 Nov 28. Acta Haematol. 2013. PMID: 23207803 Free article.
Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib.
Latagliata R, Volpicelli P, Breccia M, Vozella F, Romano A, Montagna C, Molica M, Finsinger P, Carmosino I, Serrao A, Zacheo I, Santopietro M, Salaroli A, Alimena G. Latagliata R, et al. Among authors: santopietro m. Am J Hematol. 2015 Feb;90(2):105-8. doi: 10.1002/ajh.23879. Epub 2014 Nov 19. Am J Hematol. 2015. PMID: 25349084 Free article.
69 results